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A B S T R A C T
Background
Tranexamic acid reduces haemorrhage through its antifibrinolytic effects. In a previous version of the present review, we found that
tranexamic acid may reduce mortality. This review includes updated searches and new trials.
Objectives
To assess the effects of tranexamic acid versus no intervention, placebo or other antiulcer drugs for upper gastrointestinal bleeding.
Search methods
We updated the review by performing electronic database searches (Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, EMBASE, Science Citation Index) and manual searches in July 2014.
Selection criteria
Randomised controlled trials, irrespective of language or publication status.
Data collection and analysis
We used the standard methodological procedures of the The Cochrane Collaboration. All-cause mortality, bleeding and adverse events
were the primary outcome measures. We performed fixed-effect and random-effects model meta-analyses and presented results as risk
ratios (RRs) with 95% confidence intervals (CIs) and used I² as a measure of between-trial heterogeneity. We analysed tranexamic
acid versus placebo or no intervention and tranexamic acid versus antiulcer drugs separately. To analyse sources of heterogeneity and
robustness of the overall results, we performed subgroup, sensitivity and sequential analyses.
Main results
We included eight randomised controlled trials on tranexamic acid for upper gastrointestinal bleeding. Additionally, we identified one
large ongoing pragmatic randomised controlled trial from which data are not yet available. Control groups were randomly assigned
to placebo (seven trials) or no intervention (one trial). Two trials also included a control group randomly assigned to antiulcer drugs
(lansoprazole or cimetidine). The included studies were published from 1973 to 2011. The number of participants randomly assigned
ranged from 47 to 216 (median 204). All trials reported mortality. In total, 42 of 851 participants randomly assigned to tranexamic
1Tranexamic acid for upper gastrointestinal bleeding (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
acid and 71 of 850 in the control group died (RR 0.60, 95% CI 0.42 to 0.87; P value 0.007; I² = 0%). The analysis was not confirmed
when all participants in the intervention group with missing outcome data were included as treatment failures, or when the analysis
was limited to trials with low risk of attrition bias. Rebleeding was diagnosed for 117 of 826 participants in the tranexamic acid group
and for 146 of 825 participants in the control group (RR 0.80, 95% CI 0.64 to 1.00; P value 0.07; I² = 49%). We were able to evaluate
the risk of serious adverse events on the basis of only four trials. Our analyses showed ’no evidence of a difference between tranexamic
acid and control interventions regarding the risk of thromboembolic events.’ Tranexamic acid appeared to reduce the risk of surgery in
a fixed-effect meta-analysis (RR 0.73, 95% CI 0.56 to 0.95), but this result was no longer statistically significant in a random-effects
meta-analysis (RR 0.61, 95% CI 0.35 to 1.04; P value 0.07). No difference was apparent between tranexamic acid and placebo in the
assessment of transfusion (RR 1.02, 95% CI 0.94 to 1.11; I² = 0%), and meta-analyses that compared tranexamic acid versus antiulcer
drugs did not identify beneficial or detrimental effects of tranexamic acid for any of the outcomes assessed.
Authors’ conclusions
This review found that tranexamic acid appears to have a beneficial effect on mortality, but a high dropout rate in some trials means
that we cannot be sure of this until the findings of additional research are published. At the time of this update in 2014, one large study
(8000 participants) is in progress, so this review will be much more informative in a few years. Further examination of tranexamic acid
would require inclusion of high-quality randomised controlled trials. Timing of randomisation is essential to avoid attrition bias and to
limit the number of withdrawals. Future trials may use a pragmatic design and should include all participants with suspected bleeding
or with endoscopically verified bleeding, as well as a tranexamic placebo arm and co-administration of pump inhibitors and endoscopic
therapy. Assessment of outcome measures in such studies should be clearly defined. Endoscopic examination with appropriate control of
severe bleeding should be performed, as should endoscopic verification of clinically significant rebleeding. In addition, clinical measures
of rebleeding should be included. Other important outcome measures include mortality (30-day or in-hospital), need for emergency
surgery or blood transfusion and adverse events (major or minor).
P L A I N L A N G U A G E S U M M A R Y
Tranexamic acid, an agent that promotes blood clotting, for serious or uncontrolled upper gastrointestinal bleeding
Background
Upper gastrointestinal bleeding is a common reason for emergency hospital admission. The prognosis is serious. Some patients may
die as the result of uncontrolled bleeding.
Review question
Tranexamic acid is an antifibrinolytic agent. This drug reduces the breakdown of fibrin; fibrin provides the framework for the formation
of a blood clot, which is needed to stop the bleeding. Clinical trials suggest that tranexamic acid could reduce mortality in upper
gastrointestinal bleeding.
Study characteristics
This review includes data from eight randomised trials on tranexamic acid. Two trials also assessed antiulcer drugs. Only one trial used
additional endoscopic therapy, as the remaining trials were performed before this intervention was introduced into clinical practice.
Key results
These trials found that tranexamic acid appears to have a beneficial effect on mortality, but a high dropout rate in some trials means that
we cannot be sure of these findings until additional research is published . Tranexamic acid did not reduce mortality in the trials that
included antiulcer drugs or endoscopic therapy. Additional randomised controlled trials are needed before we can determine whether
tranexamic acid has a beneficial effect on serious or uncontrolled upper gastrointestinal bleeding.
Quality of the evidence
Many patients who were randomly assigned were subsequently excluded from the assessment. The main source of bias was therefore
attrition. The overall quality of the evidence was moderate to low.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Tranexamic acid vs placebo for upper gastrointestinal bleeding
Patient or population: patients with upper gastrointestinal bleeding
Settings:
Intervention: tranexamic acid vs placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Tranexamic acid vs
placebo
Mortality
Clinical
Follow-up:median 5 days
Study population RR 0.6
(0.42-0.87)
1701
(8 studies)
⊕⊕⊕©
moderatea,b
84 per 1000 50 per 1000
(34-72)
Moderate
83 per 1000 50 per 1000
(34-71)
Rebleeding
Clinical and endoscopic
assessment
Follow-up:median 5 days
Study population RR 0.72
(0.50-1.03)
1651
(7 studies)
⊕⊕©©
lowa,b,c
177 per 1000 142 per 1000
(113-177)
Moderate
196 per 1000 157 per 1000
(125-196)
3
T
ra
n
e
x
a
m
ic
a
c
id
fo
r
u
p
p
e
r
g
a
stro
in
te
stin
a
l
b
le
e
d
in
g
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
4
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Any thromboembolic
event
Clinical and radiological
assessment
Follow-up:median 5 days
Study population RR 1.86
(0.66-5.24)
1095
(4 studies)
⊕⊕⊕©
moderatea,b
11 per 1000 20 per 1000
(7-57)
Moderate
10 per 1000 19 per 1000
(7-52)
Surgery
Number of participants
who underwent surgery
Follow-up:median 5 days
Study population RR 0.61
(0.35-1.04)
1551
(7 studies)
⊕⊕⊕©
moderatea
142 per 1000 103 per 1000
(79-135)
Moderate
154 per 1000 112 per 1000
(86-146)
Transfusion
Number needing blood
transfusion
Follow-up: median 3
weeks
Study population RR 1.02
(0.94-1.1)
931
(5 studies)
⊕©©©
very lowa,d
564 per 1000 558 per 1000
(507-620)
Moderate
583 per 1000 577 per 1000
(525-641)
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
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GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aMost trials had high risk of attrition bias.
bNot possible to evaluate because number of trials was limited.
cStatistical between-trial heterogeneity approached 50%.
dThe number of participants who needed transfusion is an indirect measure of bleeding and varies among clinical sites.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
5
T
ra
n
e
x
a
m
ic
a
c
id
fo
r
u
p
p
e
r
g
a
stro
in
te
stin
a
l
b
le
e
d
in
g
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
4
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
B A C K G R O U N D
Description of the condition
Upper gastrointestinal bleeding is a common reason for emergency
hospital admission and a common complication in hospitalised
patients (Rockall 1995; Blatchford 1997). A systematic review
of general, population-based epidemiological studies found that
the incidence of upper gastrointestinal bleeding among patients
treated with non-steroidal anti-inflammatory drugs was 0.8 per
1000 (Hernandez 2002). The risk of upper gastrointestinal bleed-
ing has been found to increase significantly with age, co-morbidity
and use of non-steroidal anti-inflammatory drugs (Yavorski 1995;
Paspatis 2000; Ng 2006). About 80% of patients with upper gas-
trointestinal bleeding will spontaneously stop bleeding, without
recurrence (Laine 1994). The highest mortality and morbidity
rates are seen in the remaining 20%, who experience recurrent or
continued bleeding. Among patients referred to endoscopy for sus-
pected upper gastrointestinal bleeding, 30-day mortality is 10%
to 14% (van Leerdam 2003; Barkun 2004; Barkun 2010).
Description of the intervention
Several endoscopic therapies have been found to be effective in
clinical trials (Kahi 2005). However, some hospital departments
may not have access to acute endoscopy. In other cases, patients
may refuse to undergo endoscopy. Identification of drugs that may
achieve haemostasis, stabilising patients until endoscopy can be
performed, is therefore essential.
How the intervention might work
Tranexamic acid reduces fibrinolysis by slowing down the conver-
sion of plasminogen to plasmin. The resulting reduction in fibri-
nolysis prevents the breakdown of blood clots, which may result in
haemostasis but increased risk of thromboembolic complications.
This drug was introduced for menorrhagia in 1968 (Vermylen
1968) and is used to reduce blood loss during surgery (Laupacis
1997; Cid 2005). A large multi-centre trial found that tranex-
amic acid reducesmortality in individuals with bleeding trauma by
9% and results in no apparent increase in thromboembolic events
(CRASH-2). It is possible that a similar effect can be achieved in
cases of upper gastrointestinal bleeding.
Why it is important to do this review
Endoscopic therapy and proton pump inhibitors serve as the cor-
nerstone in the treatment of bleeding from peptic ulcers (Lau
2013). These treatments are highlighted in recent evidence-based
guidelines (Dworzynski 2012), which do not recommend tranex-
amic acid for the management of upper gastrointestinal bleed-
ing. Randomised trials have assessed the effects of tranexamic acid
among patients with suspected or verified upper gastrointestinal
bleeding (Cormack 1973; Biggs 1976; Engquist 1979; Bergqvist
1980; Barer 1983;Holstein 1987;Hawkey 2001). Ameta-analysis
of these trials revealed that tranexamic acid reduces the risks of re-
bleeding andmortality (Henry 1989). However, results of individ-
ual trials varied considerably. Furthermore, the overall result has
been characterised as disproportionately skewed by inclusion of a
trial in which mortality in the control group was surprisingly high
(Barer 1983; Palmer 2002). We have previously published a sys-
tematic review on tranexamic acid versus placebo (Gluud 2008).
A randomised trial on tranexamic acid for upper gastrointestinal
bleeding was published after our previous meta-analysis had been
completed (Bagnenko 2011). This trial was included in a recent
review, which determined that we still have insufficient evidence
for definitive conclusions (Manno 2014). We performed this up-
dated systematic review on tranexamic acid versus placebo, cime-
tidine or lansoprazole for upper gastrointestinal bleeding.
O B J E C T I V E S
To assess the effects of tranexamic acid versus no intervention,
placebo or other antiulcer drugs for upper gastrointestinal bleed-
ing.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised trials, irrespective of language, blinding, length of
follow-up or publication status.
Types of participants
Individuals with suspected or endoscopically verified upper gas-
trointestinal bleeding, irrespective of the bleeding source.
Types of interventions
Primary analyses included trials on tranexamic acid versus placebo
or no intervention. Secondary analyses compared tranexamic acid
versus any other antiulcer drug.
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Types of outcome measures
Primary outcomes
• Mortality.
• Adverse events. We defined serious adverse events as all
adverse events considered serious by study participants or
investigators.
Secondary outcomes
• Rebleeding.
• Surgery.
Search methods for identification of studies
Electronic searches
Electronic searches of the following were performed July 2014.
• Cochrane Central Register of Controlled Trials
(CENTRAL) (Appendix 1).
• MEDLINE via Ovid SP (Appendix 2).
• EMBASE via Ovid SP (Appendix 3).
• Science Citation Index Expanded (Appendix 4).
Searching other resources
We scanned conference proceedings and reference lists from rele-
vant trials, wrote to authors of included trials and searched the In-
ternational Clinical Trials Registry Platform (ICTRP) to identify
trials on tranexamic acid (Appendix 5).
Data collection and analysis
Selection of studies
Three review authors (LLG, SLK and CB) screened search results
for potentially eligible trials and identified trials that were eligible
for inclusion. Excluded trials were listed together with the reasons
for exclusion. At each stage of the selection process, at least two
review authors independently reviewed search results and selected
trials for inclusion. Three review authors (LLG, SLK and CB)
agreed on the final list.
Data extraction and management
Two review authors (LLG and SLK) independently extracted data
using data collection forms designed to capture information spe-
cific to this review. CB verified the extracted data at this update.
Disagreements were resolved through discussion before analyses
were performed. Data on baseline participant characteristics (in-
clusion criteria, mean age, proportion of men and source of bleed-
ing), dose and duration of treatment, country of origin, publica-
tion status, funding, duration of follow-up and risk of bias were
gathered from the included trials and from correspondence with
study authors. For trials published in Russian, two review authors
(LLG and CB) extracted data obtained by machine translation
(Google translate). Dimitrinka Nikolova from the Cochrane Hep-
ato-Biliary Group read the original Russian language publication
and verified the extracted data.
Assessment of risk of bias in included studies
At least two review authors (LLG and SLK or CB) independently
assessed risk of bias in the included studies by using the risk of bias
assessment tool provided in Chapter 8 of theCochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We com-
pared these evaluations and discussed and resolved inconsistencies.
We rated the following domains separately for each of the included
studies as ’low risk of bias,’ ’high risk of bias’ or ’unclear risk of bias’
if the risk of bias was uncertain or unknown. These assessments
are reported in the ’Risk of bias’ table for each individual study
included in the Characteristics of included studies section of the
review.
• Allocation sequence was adequately generated (’sequence
generation’).
• Allocation was adequately concealed (’allocation
concealment’).
• Knowledge of allocated interventions was adequately
prevented during the study (’blinding’) (whether the trial was
described as double-blind or single-blind, and whether blinding
involved healthcare providers, outcome assessors or those
performing data extraction or data analysis).
• Incomplete outcome data were adequately addressed.
• Reports of the study were free of suggestions of selective
outcome reporting (whether clinically relevant outcome
measures were defined and reported).
• The study was apparently free of other sources of bias that
could put it at high risk of bias (e.g. potential conflicts of
interest, pharmaceutical funding/support, or both).
• Other biases (sample size calculations and registration in
clinical trial databases).
We categorised and reported the overall risk of bias of each of the
included studies according to the following.
• Low risk of bias (plausible bias unlikely to seriously alter the
results) if all criteria were met.
• Unclear risk of bias (plausible bias that raises some doubt
about the results) if one or more criteria were assessed as unclear.
• High risk of bias (plausible bias that seriously weakens
confidence in the results) if one or more criteria were not met.
We reported these assessments in the Risk of bias in included
studies section of this review.
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Measures of treatment effect
The effect measure consisted of risk ratios (RRs) with 95% confi-
dence intervals (CIs).
Unit of analysis issues
As the primary outcome measure was mortality, only trials using
a parallel-group design were included. Data on all intervention
groups were analysed separately for all trials, including those with
more than two parallel arms. Risk of selection bias was noted in
the allocation of participants to intervention or control groups and
in the administration of collateral interventions; therefore we did
not include cluster-randomised trials.
Multi-armed trials
For trials withmultiple intervention groups, we partitioned partic-
ipants into individual allocation arms to perform pair-wise com-
parisons. For example, a three-arm trial with 30 participants (10
in each arm) allocated to tranexamic acid versus placebo versus
antiulcer drugs would allow two pair-wise comparisons of tranex-
amic acid versus placebo (10 vs 10 participants) and tranexamic
acid versus antiulcer drugs (10 vs 10 participants).
Dealing with missing data
We contacted study investigators to request data on all randomly
assigned participants to perform intention-to-treat analyses. We
used simple imputation to evaluate the potential influence of miss-
ing data: imputing failures, imputing successes and worst- and
best-case scenarios (Higgins 2008).
Assessment of heterogeneity
We assessed clinical heterogeneity by examining trial conditions
on the basis of characteristics of included trials, participants and
interventions. We assessed statistical heterogeneity by using I2 sta-
tistical values and reported heterogeneity as important when the
I² statistic was > 60% (Higgins 2011).
Assessment of reporting biases
We attempted to obtain trial protocols to compare reported out-
come measures in the protocol versus those in the published trial.
For analyses with at least 10 trials, we planned to assess report-
ing biases and other dissemination biases by using funnel plots
(Higgins 2011) and to perform regression analyses by using Har-
bord’s modified test (Harbord 2006). Our analyses included only
eight trials; therefore we did not carry out a statistical analysis of
reporting bias.
Data synthesis
We performed analyses in RevMan 2014 (The Nordic Cochrane
Centre, Copenhagen, Denmark), STATA version 13 (Stata Corp.,
Texas, USA) andTrial Sequential Analysis (TheCochraneHepato-
Biliary Group, Copenhagen, Denmark). We performed all meta-
analyses using both random-effects and fixed-effect models. Fixed-
effect model meta-analyses are reported only when the results of
the two models differ (e.g. one model shows no difference between
interventions and the other shows an intervention effect).
We report the results of analyses with the total number of partic-
ipants. When it was possible to calculate an effect size, we report
this with 95% confidence intervals. When the calculated effect
size was statistically significant (defined as P value < 0.05), we state
whether the result favoured the intervention or control condition.
Subgroup analysis and investigation of heterogeneity
We performed separate analyses of trials on tranexamic acid versus
placebo or no intervention and trials on tranexamic acid versus
antiulcer drugs, as well as subgroup analyses of trials with low
risk of bias based on assessment of the separate domains. We also
analysed subgroups of trials that used endoscopic therapy and trials
published in English or Russian.
Sensitivity analysis
We performed two further analyses to determine the effects of
missing outcome data and a per-protocol analysis to evaluate the
influence of missing data. In the first scenario, all participants in
the intervention arm with missing outcome data were included
as treatment failures and participants in the control group with
missing outcome data were considered as treatment successes. In
the per-protocol analyses, we excluded participants with missing
outcome data. We performed a post hoc analysis that excluded a
trial with a very high event rate in the control group (Barer 1983).
Trial sequential analysis
We performed a post hoc trial sequential analysis to determine
the risk of bias associated with cumulative testing and to evaluate
futility in the assessment of mortality and bleeding (Higgins 2008;
Wetterslev 2008). We performed the analysis with power set to
80%, alpha to 5% and model-based diversity and with relative risk
reduction (RRR) to 30%. We set the control incidence to 10% for
the analysis of mortality and to 30% for the analysis of bleeding.
’Summary of findings’ tables
We prepared a ’Summary of findings’ table (Guyatt 2008) using
GRADEpro software (Gradepro 3.6) and we included informa-
tion on the results of our primary outcomes in relation to risk of
heterogeneity, duration of follow-up and quality of the evidence.
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R E S U L T S
Description of studies
Results of the search
The original electronic searches identified 84 hits, and the up-
dated search 37 hits (Appendix 6). The manual search identified
one additional record. After reading the titles and abstracts, we
retrieved 15 records for further assessment. One record referred to
an ongoing trial (ISRCTN11225767) on tranexamic acid for gas-
trointestinal bleeding (Characteristics of ongoing studies).We will
include this trial in future updates if the results become available
(Figure 1). We excluded four records that did not assess tranex-
amic acid for upper gastrointestinal bleeding. In total, we included
eight randomised controlled trials in our analyses (Cormack 1973;
Biggs 1976; Engquist 1979; Bergqvist 1980; Barer 1983; Holstein
1987; Hawkey 2001; Bagnenko 2011). We received additional
information about study design and outcomes from the primary
investigators of one of the included trials (Hawkey 2001). For the
remaining trials, we had access only to published data. The in-
cluded trials were published as full paper articles, from 1973 to
2011. One trial was published in Russian (Bagnenko 2011), and
the remaining in English.
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Figure 1. Study flow diagram.
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Included studies
Design
All trials were randomised, parallel arm. One trial was open (
Bagnenko 2011), and the remaining trials were double blind with
a placebo control.
Sample sizes
The numbers of participants randomly assigned ranged from 47
to 216 (median 204).
Setting
All trials were performed at hospitals.
Participants
The trials included participants admitted with suspected upper
gastrointestinal bleeding confirmed by endoscopy or clinically
through gastric lavage, hematemesis or melena. Participants with
previous or ongoing thromboembolic disease or renal disease and
pregnant women were excluded from the trials. Three trials in-
cluded only participants with severe bleeding (Engquist 1979;
Bergqvist 1980; Bagnenko 2011). In the remaining trials, propor-
tions of participants with circulatory involvement ranged from
1% to 21%. Mean participant age ranged from 56 to 62 years
in the tranexamic acid groups and from 56 to 65 years in the
control groups. Five trials reported that a proportion of partici-
pants had oesophageal varices (mean proportion 8%, range 5% to
16%). In four trials (Barer 1983; Holstein 1987; Hawkey 2001;
Bagnenko 2011), participants underwent endoscopy within 24
hours after admission. One trial reported that 12% of included
participants did not undergo the planned endoscopy. Two trials
evaluated participants with endoscopy but did not specify the time
frame (Engquist 1979; Bergqvist 1980). The remaining two tri-
als did not include an endoscopic evaluation (Cormack 1973) or
had access to endoscopy only during a portion of the trial (Biggs
1976).
Interventions
Tranexamic acidwas administered intravenously in one trial (Barer
1983) and orally in three trials (Cormack 1973; Bergqvist 1980;
Hawkey 2001). The remaining trials used intravenous followed
by oral administration. The total daily dose of tranexamic acid
ranged from 4 to 8 g. Duration of therapy ranged from two to
seven days.
Comparisons
One trial included a no intervention control group (Bagnenko
2011), and the remaining trials included a placebo control. Two
trials were multi-armed and included control groups randomly
assigned to the histamine receptor (H2) agonist cimetidine (Barer
1983) or the proton pump inhibitor lansoprazole alone or with
tranexamic acid (Hawkey 2001). One trial allowed co-interven-
tion with the histamine receptor agonist famotidine (Bagnenko
2011). In five trials, a variety of co-interventions, including no-
valuzide and cimetidine or ranitidine, were administered to par-
ticipants in both treatment arms (Cormack 1973; Biggs 1976;
Engquist 1979; Bergqvist 1980; Holstein 1987). Two trials used
endoscopic therapy to control bleeding (Hawkey 2001; Bagnenko
2011).
Outcomes
One trial reported endoscopically verified rebleeding (Bagnenko
2011). Another trial reported rebleeding as assessed by hemateme-
sis, melena or hypotension plus a drop in haemoglobin or rebleed-
ing seen at endoscopy (Hawkey 2001). Two trials defined rebleed-
ing on the basis of a drop in haemoglobin (Holstein 1987) or a
drop in haemoglobin, hematemesis or melena (Barer 1983). The
remaining trials did not define rebleeding.
Excluded studies
We excluded four trials that were published as full paper arti-
cles (Hollanders 1982; Tam 1989; Adachi 2001; Sabovic 2003).
These trials were excluded because they were observational, as-
sessed certrexate or did not include participants with upper gas-
trointestinal bleeding (Excluded studies).
Risk of bias in included studies
Allocation
One trial (Bagnenko 2011) reported an adequate method for allo-
cation sequence generation (Figure 2). The remaining trials did not
describe how the allocation sequence was generated. One trial did
not describe how allocation was concealed (Bagnenko 2011). In
the remaining trials, allocation was adequately concealed through
double-blind administration of the intervention or placebo.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Blinding
One trial was open (Bagnenko 2011). The remaining trials were
double blind with a placebo control.
Incomplete outcome data
Attrition was one of the main sources of bias. Five trials reported
losses to follow-up (Engquist 1979; Bergqvist 1980; Barer 1983;
Holstein 1987; Hawkey 2001). Three trials gave the impression
that no dropouts or withdrawals had occurred, although this was
not specifically reported (Cormack 1973; Biggs 1976; Bagnenko
2011).One in five participants (20%)were withdrawn or excluded
after randomisation.Reasons for exclusion included lack of verified
bleeding, malignant disease and terminal illness, or the treatment
was administered too late.
Selective reporting
One trial did not report bleeding and was classed as having high
risk of reporting bias (Bergqvist 1980).
Other potential sources of bias
None of the trials had other potential sources of bias.
Effects of interventions
See: Summary of findings for the main comparisonTranexamic
acid vs placebo for upper gastrointestinal bleeding; Summary of
findings 2Tranexamic acid vs cimetidine or lansoprazole for upper
gastrointestinal bleeding
Comparison 1. Tranexamic acid versus placebo
Primary outcomes
Mortality
All trials reported mortality (Analysis 1.1). Forty-two of 851 par-
ticipants randomly assigned to tranexamic acid and 71 of 850
in the control group died. The fixed-effect meta-analysis showed
that tranexamic acid reduced mortality (RR 0.60, 95% CI 0.42
to 0.87; P value 0.007). No statistical heterogeneity was noted
between trials (I² = 0%).
Sensitivity analyses and trial sequential analysis
The analysis was not confirmed in a scenario analysis in which
all participants with missing outcome data were included as treat-
ment failures (Analysis 1.2), but it was confirmed in a per-protocol
analysis (data not shown).
Analyses of studies with low risk of bias confirmed that attrition
was the main source of bias (Analysis 1.3). The single remaining
trial with low risk of attrition bias (Hawkey 2001) found no effects
of the intervention. A similar result was seen when trials that used
endoscopic therapy to control bleeding were analysed (Analysis
1.4). No difference (test for subgroup differences P value 0.67)
was noted between trials published in English and those translated
from Russian (Analysis 1.5).
One of the trials has been criticised for reporting a high control
group event rate (Barer 1983; Palmer 2002). This trial included
516 participants and reported a large weight in the analysis (49%).
In a post hoc analysis that excluded this trial, tranexamic acid was
seen to have no effect on mortality (RR 0.73, 95% CI 0.45 to
1.19; analysis not shown). In our post hoc trial sequential analysis
(Figure 3), the required information size was not met, suggesting
that the meta-analysis is inconclusive.
13Tranexamic acid for upper gastrointestinal bleeding (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Trial sequential analysis of eight trials on tranexamic acid versus placebo or no intervention.
Outcome measure is mortality. Analysis was performed with alpha 5% and power 80%. Model-based
heterogeneity correction was 0%, relative risk reduction 30% and control group incidence 10%. Graph shows
the Z-curve, which is the cumulative result of analysis with trials added according to year of publication.
Horizontal line represents ’traditional’ 5% level of significance, and inward sloping red line shows trial
sequential monitoring boundary. Vertical line represents required information size. Analysis shows that the Z-
curve crosses the trial sequential monitoring boundary, suggesting that the result of the meta-analysis is
confirmed when analysis is adjusted for cumulative testing. Total number of included participants (N = 1701) is
only 62% of required information size (N=2714). The meta-analysis therefore remains inconclusive.
Bleeding
Seven trials reported rebleeding (Analysis 1.6). In total, rebleeding
was diagnosed for 117 of 826 participants in the tranexamic acid
group and for 146 of 825 participants in the control group.
Sensitivity analyses and trial sequential analysis
The difference was not statistically significant (RR 0.72, 95% CI
0.50 to 1.03; P value 0.07). A similar conclusion was reached in
worst-case scenario analysis (Analysis 1.7) and per-protocol analy-
sis (data not shown). Analyses of trials with low risk of bias found
no effects of tranexamic acid on bleeding (Analysis 1.8), and no
differences were noted between trials stratified according to use of
endoscopic therapy (Analysis 1.9) or language (Analysis 1.10). In
the trial sequential analysis (Figure 4), 95% of the required infor-
mation size was reached. This analysis suggested that the meta-
analysis was inconclusive.
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Figure 4. Trial sequential analysis of seven trials on tranexamic acid versus placebo or no intervention.
Outcome measure is bleeding. Analysis was performed with alpha 5% and power 80%. Model-based
heterogeneity correction was 53%, relative risk reduction 30% and control group incidence 10%. Graph shows
the Z-curve, which is the cumulative result of analysis with trials added according to year of publication.
Horizontal line represents ’traditional’ 5% level of significance, and inward sloping red line shows trial
sequential monitoring boundary. Vertical line represents required information size. Analysis shows that the Z-
curve does not cross the trial sequential monitoring boundary, and the total number of participants (N = 1651)
is 95% of required information size (N = 1734). The meta-analysis therefore remains inconclusive.
Adverse events
Several participants randomly assigned to tranexamic acid expe-
rienced abdominal pain, nausea, vomiting and thrombophlebitis
at the injection site (Table 1). We were unable to perform meta-
analyses on these adverse events because data were not provided
for both treatment and control groups.
Three trials (Analysis 1.13) on 1048 participants reported throm-
boembolic events (Engquist 1979; Barer 1983; Holstein 1987).
Among participants randomly assigned to tranexamic acid, two
cases of myocardial infarction, two cases of pulmonary embolism
and one case of cerebral infarction occurred. In the placebo group,
two cases of myocardial infarction and two cases of cerebral in-
farction were recorded. When data on these serious thromboem-
bolic events were combined, the difference was not statistically
significant (RR 1.37, 95% CI 0.36 to 5.28; Analysis 1.11). Six
cases of deep venous thrombosis occurred among participants ran-
domly assigned to tranexamic acid compared with two cases in the
placebo group (RR 2.32, 95% CI 0.60 to 8.89; Analysis 1.12).
The numbers of participants with any thrombotic event were not
significantly different between treatment and control groups (RR
1.86, 95% CI 0.66 to 5.24; Analysis 1.13).
Secondary outcomes
Surgery
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Seven studies with 1551 participants reported the numbers of par-
ticipants who required surgery (Analysis 1.14). Between-trial het-
erogeneity was important (I² = 63%). Tranexamic acid appeared to
reduce the risk of surgery in a fixed-effect meta-analysis (RR 0.73,
95% CI 0.56 to 0.95), but this result was no longer statistically
significant at the 5% level, when a random-effects meta-analysis
was used (RR 0.61, 95% CI 0.35 to 1.04; Analysis 1.14).
Transfusions
We planned to analyse the transfusion requirements of included
participants, but we did not identify the necessary data. We there-
fore performed a post hoc analysis of the total numbers of partic-
ipants who needed at least one blood transfusion (Analysis 1.15)
and found no apparent differences between tranexamic acid and
placebo (RR 1.02, 95% CI 0.94 to 1.11 in 931 participants; five
studies; I² = 0%).
Comparison 2. Tranexamic acid versus antiulcer
drugs (cimetidine or lansoprazole)
Primary outcomes
Mortality and rebleeding
Two trials compared tranexamic acidwith cimetidine (Barer 1983)
or lansoprazole (Hawkey 2001). These trials found no significant
effects of tranexamic acid on mortality (RR 0.91, 95% CI 0.50
to 1.64; 720 participants; I² = 0%; Analysis 2.1) or bleeding (RR
0.87, 95% CI 0.64 to 1.20; I² = 0%; Analysis 2.2).
Adverse events
Wewere unable to performmeta-analyses on adverse events (Table
1). Barer 1983 reported one case of fatal stroke in the tranex-
amic acid group and two cases of confusion in the control group.
Hawkey 2001 reported no adverse events in the tranexamic acid
or control groups.
Surgery and transfusions
Trials comparing tranexamic acid versus cimetidine or lansopra-
zole (Barer 1983; Hawkey 2001) found no differences between
allocation groups regarding the need for surgery (RR 0.83, 95%
CI 0.54 to 1.26; 720 participants; two studies; I² = 3%; Analysis
2.3) or blood transfusion (RR 0.97, 95% CI 0.78 to 1.22; 720
participants; two studies; I² = 64%; Analysis 2.4).
’Summary of findings’ tables
As shown in the ’Summary of findings’ tables on tranexamic acid
versus placebo (Summary of findings for the main comparison) or
cimetidine or lansoprazole (Summary of findings 2), the quality
of the evidence was downgraded to moderate or low because of
risk of bias.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Tranexamic acid vs cimetidine or lansoprazole for upper gastrointestinal bleeding
Patient or population: patients with upper gastrointestinal bleeding
Settings:
Intervention: tranexamic acid vs cimetidine or lansoprazole
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Tranexamic acid vs
cimetidine or lansopra-
zole
Mortality
Number of participants
who died
Follow-up:median 5 days
Study population RR 0.91
(0.50-1.64)
720
(2 studies)
⊕⊕⊕©
moderate
61 per 1000 56 per 1000
(31-101)
Moderate
48 per 1000 44 per 1000
(24-79)
Rebleeding
Clinical and endoscopic
assessment
Follow-up:median 5 days
Study population RR 0.87
(0.64-1.2)
720
(2 studies)
⊕⊕⊕©
moderatea,b
188 per 1000 166 per 1000
(121-226)
Moderate
161 per 1000 142 per 1000
(103-193)
1
7
T
ra
n
e
x
a
m
ic
a
c
id
fo
r
u
p
p
e
r
g
a
stro
in
te
stin
a
l
b
le
e
d
in
g
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
4
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Surgery
Number of participants
who underwent surgery
Follow-up:median 5 days
Study population RR 0.83
(0.54-1.26)
720
(2 studies)
⊕⊕⊕©
moderatea,b
139 per 1000 115 per 1000
(79-168)
Moderate
105 per 1000 87 per 1000
(60-127)
Transfusion
Number of participants
who required at least 1
blood transfusion
Follow-up:median 5 days
Study population RR 0.97
(0.78-1.22)
720
(2 studies)
⊕⊕©©
lowa,b,c
573 per 1000 579 per 1000
(510-654)
Moderate
599 per 1000 605 per 1000
(533-683)
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aHigh risk of bias based on assessment of attrition.
bNot possible to evaluate because number of trials was limited.
cThis outcome measure is a surrogate estimate for bleeding.
1
8
T
ra
n
e
x
a
m
ic
a
c
id
fo
r
u
p
p
e
r
g
a
stro
in
te
stin
a
l
b
le
e
d
in
g
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
4
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
D I S C U S S I O N
Summary of main results
This review includes eight randomised controlled trials and a total
of 1701 participants with acute upper gastrointestinal bleeding.
The meta-analyses found that tranexamic acid appears to have a
beneficial effect on mortality, but a high dropout rate in some tri-
als means that we cannot be sure of this until additional research
is published. Reduced mortality did not clearly reflect reduced
bleeding or surgery. The result of the primary meta-analysis was
not stable in analyses that adjusted for risk of attrition bias or in
trial sequential analyses. When trials with high risk of attrition
bias were removed, only one trial was left (Hawkey 2001) in the
analysis, so although we may need to be cautious about the poten-
tial effects of dropouts, the evidence is still fairly strong in favour
of tranexamic acid. Likewise, only two of the included trials used
endoscopic therapy (Hawkey 2001; Bagnenko 2011). These trials
found no clear effects of tranexamic acid on bleeding was noted
and that attrition biasmay affect the assessment ofmortality, there-
fore the combined evidence does not allow any recommendations
to be made. Additional randomised controlled trials are needed to
determine the effects of tranexamic acid. A large randomised dou-
ble-blind trial on tranexamic acid for gastrointestinal bleeding is
ongoing (ISRCTN11225767). This trial has started to randomly
assign the first participants. Results of this trial are expected to
finally confirm or refute the effects of tranexamic acid for individ-
uals with upper gastrointestinal bleeding.
Overall completeness and applicability of
evidence
During recent years, standard care and assessment of outcomes
have changed considerably (Dworzynski 2012). Previously, pa-
tients were not offered full diagnostic endoscopy or endoscopic
interventions that are used as standard care today. It is noteworthy
that the trial that is the most favourable towards tranexamic acid
was published in 1983 (Barer 1983). The clinical question today
is not whether tranexamic acid is better than placebo, but whether
tranexamic acid is better than or may be used in combination with
current treatments. One of the included trials found no signifi-
cant difference between tranexamic acid and lansoprazole when
used alone, or when the two treatments were combined (Hawkey
2001). This trial was not designed to assess clinical outcomes, and
its statistical power may well have been too small to detect clin-
ically relevant effects. On the other hand, this trial does suggest
that additional research is necessary.
Several reasons may explain why we found that tranexamic acid
reduces mortality but not bleeding. One possible explanation is
that tranexamic acid may be effective in subgroups of patients with
a serious prognosis. One of the included trials assessed the influ-
ence of the severity of bleeding on the intervention effect (Hawkey
2001). This trial included 414 participants with suspected upper
gastrointestinal bleeding and asked admitting investigators to clas-
sify participant risk as high or low on the basis of their presenta-
tion. No specific criteria were used. Overall, high-risk participants
were more likely to die or need surgery. The effect of tranexamic
acid was not related to risk stratification.
Quality of the evidence
In clinical guidelines on the management of upper gastrointesti-
nal non-variceal bleeding, tranexamic acid may be considered, but
it is not recommended as routine therapy (Palmer 2002; Barkun
2003). This treatment generally is not recommended for variceal
bleeding, and in several trials, participants with varices were ex-
cluded after randomisation.However,meta-analyses in the present
review include participants with upper gastrointestinal bleeding
due to oesophageal varices. No significant association was found
between treatment effect and the proportion of participants with
varices. These analyses are only hypothesis generating but suggest
that the effects of tranexamic acid on mortality may also be seen in
this patient group. Likewise, we found no significant differences
between trials in which participants received tranexamic acid in a
daily dose of 12 g for two days and those in which the dose was 4
g for seven days. It may be interesting to determine whether dose
or treatment duration is related to the risk of thromboembolic
events, but we did not have sufficient data to analyse this question.
Vested interests were reported in some of the included trials. We
were unable to identify specific design features that introduced
bias due to vested interests and the fact that we included only eight
trials limited the possibility of further analyses. Nevertheless, we
cannot exclude that this factor can lead to bias. On the other hand,
the trial that received full funding (Hawkey 2001) found no effect
of tranexamic acid on any of the outcomes assessed.The largest
trials received tranexamic acid and placebo from pharmaceutical
companies (Barer 1983; Hawkey 2001). The trial with the most
positive assessment of tranexamic acid received only medications
(Barer 1983).
Mortality is an outcome measure that is relatively stable in relation
to performance and ascertainment bias, but not to attrition bias.
We found that attrition was the main source of bias. Included
trials randomly assigned participants early, and many excluded
participants after the source of bleeding had been identified by
endoscopy. Exclusion of participants appeared to be done before
blinding was broken, although this is not specifically stated. As
the result of risk of bias and clinical heterogeneity between trials,
which is inevitable given that trials were conducted over several
decades, the overall quality of the evidence was deemed moderate
or low (Summary of findings for the main comparison; Summary
of findings 2).
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Potential biases in the review process
Potential biases in the review process are limited. In particular, we
attempted to avoid bias in identification and selection of trials,
but one possible limitation is that despite exhaustive searching,
it is possible that other trials have been conducted, and although
we searched extensively, we did not identify unpublished trials
or trials published in abstract form. We included only one paper
that was published in Russian (Bagnenko 2011). Remaining trials
were published in English. Because the number of identified trials
was limited, we were not able to analyse the risk of publication
bias. In theory, meta-analyses are observational, which may lead
to biases. A written protocol is necessary to determine biases in
the review process and in general, the original protocol must be
followed. However, we made methodological changes to our pro-
tocol that were based on recent evidence and guidelines (Guyatt
2008; Higgins 2008; Higgins 2011). These changes were mainly
related to assessment of risk of bias. We also performed post hoc
sequential analyses to improve assessment of biases.
Agreements and disagreements with other
studies or reviews
Although our review methods did include assessment of all re-
ported adverse events, we did not carry out a separate search for
adverse effects; therefore one of the most important limitations
of the present review is the fact that information about adverse
events was limited. The recent debate on the use of antifibrinolytic
drugs highlights the need for valid safety data. In 2006, an observa-
tional study of patients undergoing revascularisation was reported
(Mangano 2006). This study included 1295 participants who re-
ceived aprotinin and 822 who received tranexamic acid. Multi-
variable analyses found that aprotinin, but not tranexamic acid,
significantly increased the risk of renal failure and cardiovascular
or cerebral adverse events. Although results support the safety of
tranexamic acid, the participant cohort was considerably different
from that included in the present review. In particular, the trials
included in the present review excluded participants with previ-
ous thromboembolic or renal disease. Therefore, it may be argued
that one of the most important limitations of the present review
is that limited information about adverse events was available. Al-
though we found no significant association between tranexamic
acid and risk of thromboembolic events, our analyses did not have
sufficient statistical power to allow clear inferences. Theoretically,
tranexamic acid increases the risk of thrombosis due to unopposed
fibrin generation. Case reports have associated tranexamic acid
with thromboembolic events, which may be fatal (Rydin 1976;
Agnelli 1982; Endo 1988; Woo 1989; Taparia 2002). The trials
in the present review excluded participants with previous throm-
boembolic events, although this is not generally accepted as a con-
traindication in clinical practice. Likewise these trials excluded
participants with renal disease. One observational study has as-
sessed the effects of tranexamic acid on patients undergoing dial-
ysis. Tranexamic acid seems relatively safe to use in this patient
group. However, the study included only 20 participants, so ad-
ditional evidence is needed (Sabovic 2003).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review found no evidence to support or refute the use
of tranexamic acid for upper gastrointestinal bleeding, in terms
of mortality, bleeding, surgery or transfusion requirements. We
found limited information about adverse events. At present,
tranexamic acid cannot be recommended for routine clinical prac-
tice.
Implications for research
This review found no evidence that tranexamic acid offers benefit
to patients with upper gastrointestinal bleeding in terms ofmortal-
ity, bleeding, surgery or requirement for blood transfusion. At the
time of this update in 2014, additional large pragmatic randomised
trials seem warranted. We are aware of one large study (8000 par-
ticipants) that is in progress, so this review will be much more in-
formative in a few years.However, proton pump inhibitors and en-
doscopic interventions for severe gastrointestinal bleeding, includ-
ing injection and thermal andmechanical methods such as haemo-
clips, may serve as alternative effective interventions (Dworzynski
2012).
Further examination of the efficacy and safety of tranexamic acid
would involve high-quality randomised controlled trials. The tim-
ing of randomisation is essential in avoiding attrition bias and lim-
iting the number of withdrawals. The trial may use a pragmatic
design and include all participants with suspected bleeding based
on haemoglobin levels, gastric lavage, hematemesis or melena. Al-
ternatively, only participants with endoscopically verified bleeding
may be randomly assigned. The pragmatic approach could mean
inclusion of participants with concomitant disease who may have
higher risk of bleeding. When such participants are excluded from
trials, we may overestimate benefits and underestimate adverse
events. Therefore the advantage of a pragmatic approach would be
that investigators could assess whether the intervention works in
these patients, that is, such trials would have high external validity.
Future trials should assess tranexamic acid delivered orally or intra-
venously over an appropriate length of time. The trials included in
this review assessed a daily dose of up to 16 to 42 g. A placebo arm
(for comparison with tranexamic acid) should be included, and
interventions should be administered in accordance with current
treatment recommendations. Accordingly, co-interventions such
as proton pump inhibitors and endoscopic therapy must be of-
fered. Assessment of outcome measures should be clearly defined,
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and reports of adverse events should be included. Endoscopic ex-
amination with appropriate control of severe bleeding should be
included, and endoscopic verification of clinically significant re-
bleeding should be performed. In addition, clinical measures of
rebleeding should be included. Other important outcome mea-
sures include mortality (30-day or in-hospital), along with need
for emergency surgery, blood transfusion and adverse events (ma-
jor or minor).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bagnenko 2011
Methods Randomised trial on tranexamic acid vs no intervention
Participants Inclusion criteria: patients admitted with endoscopically verified severe upper gastroin-
testinal bleeding
Number of participants randomly assigned: 47
Mean age tranexamic acid/control: 62/64 years
Proportion:
• of men: 62%
• with peptic ulcer: 100%
• with oesophageal varices: 0%
• with massive bleeding: 100%
Interventions Tranexamic acid 10 mg/kg IV or oral 3 times/d vs no intervention
Outcomes All-cause mortality, rebleeding and surgery
Endoscopy Performed within 24 hours of admission
Definition of re-bleeding Endoscopically verified bleeding
Duration of therapy 3 days
Notes No funding reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Open
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open
24Tranexamic acid for upper gastrointestinal bleeding (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bagnenko 2011 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up
Selective reporting (reporting bias) Low risk Mortality and bleeding are reported
Other bias Low risk No other apparent biases are reported
Barer 1983
Methods Randomised trial on tranexamic acid vs cimetidine vs placebo
Participants Inclusion criteria: patients admitted with upper gastrointestinal bleeding confirmed by
observation of haematemesis or melena
Number of participants randomly assigned: 516
Mean age: 60-63 years
Proportion:
• of men: 65%
• with peptic ulcer: 58%
• with oesophageal varices: 5%
• with massive bleeding: 13%
Interventions Tranexamic acid 1 g IV 4 times/d then 1 g orally 4 times/d vs cimetidine 400 mg IV 4
times/d then 400 mg orally 4 times/d vs placebo
Outcomes All-cause mortality, rebleeding, surgery and adverse events
Endoscopy Performed within 24 hours of admission
Definition of re-bleeding Severe hematemesis or fresh melena or a fall in haemoglobin of at least 2 g/dL within 24
hours after the first day of admission
Duration of therapy 7 days
Notes Kabi Vitrum Ltd and Smith Kline and French supplied medications; details of funding
not supplied
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation sequence based on random
numbers
Allocation concealment (selection bias) Low risk Central packaging of coded drug contain-
ers
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Barer 1983 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blinding (using placebo)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel blinded (using
placebo)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessed in a blinded manner
(using placebo)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk In total, 99 participants were excluded after
randomisation.Reporting of follow-up and
handling of missing outcome data are clear
Selective reporting (reporting bias) Low risk Mortality and bleeding are reported
Other bias Low risk No other apparent biases are reported
Bergqvist 1980
Methods Randomised trial on tranexamic acid vs placebo
Participants Inclusion criteria: patients admitted with massive upper gastrointestinal bleeding con-
firmed by haematemesis or melena and circulatory involvement (criteria not specified)
Number of participants randomly assigned: 50
Mean age tranexamic acid/placebo: 61/58 years
Proportion:
• of men: 79%
• with peptic ulcer: 65%
• with oesophageal varices: 7%
• with massive bleeding: not reported
Interventions Tranexamic acid 2 g orally 6 times daily vs placebo
Outcomes All-cause mortality and surgery
Endoscopy Performed after admission (time frame not specified)
Definition of re-bleeding Not described
Duration of therapy 2 days
Notes No funding reported
Risk of bias
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Bergqvist 1980 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk Blinded administration of tranexamic acid
or placebo
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind placebo-controlled trial
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel blinded (using
placebo)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessed in a blinded manner
(using placebo)
Incomplete outcome data (attrition bias)
All outcomes
High risk Outcomes for participants who were ex-
cluded or withdrawn from treatment
(14%) are not reported
Selective reporting (reporting bias) High risk Continued bleeding or rebleeding is not re-
ported
Other bias Low risk No other apparent biases are reported
Biggs 1976
Methods Randomised trial comparing tranexamic acid vs placebo
Participants Inclusion criteria: patients admitted with upper gastrointestinal bleeding observed by
medical officer or confirmed by gastric lavage or observation of melena
Number of participants randomly assigned: 200
Mean age: not reported
Proportion:
• of men: 78%
• with peptic ulcer: 54%
• with oesophageal varices: 6%
• with massive bleeding: 21%
Interventions Tranexamic acid 1 g IV and 1 g orally 4 times/d then 1 g orally 4 times/d vs placebo
Outcomes All-cause mortality, rebleeding, surgery and adverse events
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Biggs 1976 (Continued)
Endoscopy Some participants were evaluated with full endoscopy (time frame and number not
specified). Early in the trial, endoscopy was unavailable
Definition of re-bleeding Not described
Duration of therapy 5 days
Notes Funding from Fauldings Australia Ltd
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk Blinded administration of tranexamic acid
or placebo
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blinding (using placebo)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel blinded (using
placebo)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessed in a blinded manner
(using placebo)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals or exclusions are reported
Selective reporting (reporting bias) Low risk Mortality and bleeding are reported
Other bias Low risk No other apparent biases are reported
Cormack 1973
Methods Randomised trial comparing tranexamic acid vs placebo
Participants Inclusion criteria: patients admitted with upper gastrointestinal bleeding confirmed by
haematemesis or melena
Number of participants randomly assigned: 150
Mean age: not reported
Proportion of:
• men: 67%
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Cormack 1973 (Continued)
• with peptic ulcer: not reported
• with oesophageal varices: not reported
• with massive bleeding: 11%
Interventions Tranexamic acid 1.5 g orally 4 times/d vs placebo
Outcomes All-cause mortality. Continued bleeding, rebleeding and surgery reported only as a com-
posite outcome
Endoscopy Not performed
Definition of re-bleeding Not defined
Duration of therapy 7 days
Notes Funding from AB Kabi, Stockholm, Sweden
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk Blinded administration of tranexamic acid
or placebo
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blinding (using placebo)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel blinded (using
placebo)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessed in a blinded manner
(using placebo)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals or dropouts are reported
Selective reporting (reporting bias) Low risk Mortality and bleeding are reported
Other bias Low risk No other apparent biases are reported
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Engquist 1979
Methods Randomised trial comparing tranexamic acid vs placebo
Participants Inclusion criteria: patients admitted withmassive upper gastrointestinal bleeding defined
as circulatory embarrassment, loss of 1800 mL blood (4 blood units), or haemoglobin
concentration lowered by at least 30 g/L
Number of participants randomly assigned: 204
Mean age tranexamic acid/placebo: 59/56 years
Proportion:
• of men: 78%
• with peptic ulcer: 47%
• with oesophageal varices: 16%
• with massive bleeding: 100%
Interventions Tranexamic acid 1 g IV 6 times/d then 1.5 g orally 4 times/d vs placebo
Outcomes Mortality, bleeding, surgery and adverse events
Endoscopy Performed (time frame not specified)
Definition of re-bleeding Not defined
Duration of therapy 7 days
Notes Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk Blinded administration of tranexamic acid
or placebo
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blinding (using placebo)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel blinded (using
placebo)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessed in a blinded manner
(using placebo)
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Engquist 1979 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Outcome measures are not reported for
participants who were withdrawn or ex-
cluded (27%)
Selective reporting (reporting bias) Low risk Mortality and bleeding are reported
Other bias Low risk No other apparent biases are reported
Hawkey 2001
Methods Randomised trial comparing tranexamic acid alone vs lansoprazole vs tranexamic acid
and lansoprazole vs placebo
Participants Inclusion criteria: patients admitted with suspected upper gastrointestinal bleeding
Number of participants randomly assigned: 206
Mean age tranexamic acid/control groups: 58/58 years
Proportion:
• of men: 61%
• with peptic ulcer: 37%
• with oesophageal varices: 14%
• with massive bleeding: 16%
Interventions Tranexamic acid 2 g orally (bolus) then 1 g orally 4 times/d vs lansoprazole 60 mg orally
(bolus) then 30 mg orally vs tranexamic acid and lansoprazole vs placebo
Outcomes All-cause mortality, bleeding-related mortality and surgery. Adverse events are reported
without information about intervention arms
Endoscopy Endoscopy was performed on the day after admission or earlier for 359 of 414 included
participants. The number of participants who were not evaluated with endoscopy was
12 for placebo and 21 for tranexamic acid
Definition of re-bleeding New haematemesis, melena or hypotension plus a drop in haemoglobin or rebleeding
seen at endoscopy
Duration of therapy 4 days
Notes Funding from Lederle Laboratories
Additional data received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
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Hawkey 2001 (Continued)
Allocation concealment (selection bias) Low risk Blinded administration of tranexamic acid
or placebo
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Double blinding (using placebo)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel blinded (using
placebo)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessed in a blinded manner
(using placebo)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Although several participants were with-
drawn or lost to follow-up, all randomly as-
signed participants are accounted for
Selective reporting (reporting bias) Low risk Mortality and bleeding are reported
Other bias Low risk No other apparent biases are reported
Holstein 1987
Methods Randomised trial comparing tranexamic acid vs placebo
Participants Inclusion criteria: patients admitted with suspected (criteria not specified) upper gas-
trointestinal bleeding. After randomisation, endoscopy was performed, and all patients
without a benign gastric or duodenal bleeding source were excluded
Number of participants randomly assigned: 128
Mean age tranexamic acid/placebo: 62/65 years
Proportion:
• of men: 70%
• with peptic ulcer: 90%
• with oesophageal varices: 0%
• with massive bleeding: 1%
Interventions Tranexamic acid 1 g IV 6 times/d then 1.5 g orally 4 times/d vs placebo
Outcomes Mortality, bleeding, surgery and adverse events
Endoscopy Performed within 24 hours of admission
Definition of re-bleeding Drop in haemoglobin of at least 20 g/L
Duration of therapy 6 days
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Holstein 1987 (Continued)
Notes KabiVitrum AB supplied tranexamic acid and placebo and gave advice about the trial
design
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk Blinded administration of tranexamic acid
or placebo
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blinding (using placebo)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel blinded (using
placebo)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessed in a blinded manner
(using placebo)
Incomplete outcome data (attrition bias)
All outcomes
High risk Outcome measures are not reported for
participants who were excluded or lost to
follow-up (47%)
Selective reporting (reporting bias) Low risk Mortality and bleeding are reported
Other bias Low risk No other apparent biases are reported
IV: intravenous.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adachi 2001 Randomised trial on lansoprazole alone or with cetraxate for healing of peptic ulcers
Hollanders 1982 Randomised trial on tranexamic acid for ulcerative colitis
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(Continued)
Sabovic 2003 Non-randomised trial on tranexamic acid as adjunctive therapy for upper gastrointestinal bleeding in patients
with renal failure
Tam 1989 Randomised trial on cetraxate vs ranitidine for treatment of patients with gastric ulcer
Characteristics of ongoing studies [ordered by study ID]
ISRCTN11225767
Trial name or title Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double-
blind placebo-controlled trial (Haemorrhage ALleviation with Tranexamic acid? IntesTinal system HALT-
IT)
Methods Randomised double-blind trial
Participants • Inclusion criteria: all adult patients with acute significant upper or lower gastrointestinal bleeding
when the responsible clinician is substantially uncertain as to the appropriateness of antifibrinolytic agents
in the patient
• Exclusion criteria: fundamental eligibility criterion: the responsible clinician’s ’uncertainty’ as to
whether an antifibrinolytic agent should be used in a particular patient with upper or lower gastrointestinal
bleeding
Interventions Tranexamic acid (loading dose 1 g over 10 minutes then infusion of 3 g over 24 hours) or matching placebo
Outcomes Death in hospital within 28 days of randomisation (cause-specific mortality will also be recorded)
Starting date Date of first enrolment: January 2 2013
Contact information Professor Ian Roberts, haltit@lshtm.ac.uk
Ms Haleema Shakur, haltit@lshtm.ac.uk
Target sample size 8000 participants
Sponsor London School of Hygiene and Tropical Medicine (UK)
Conditions assessed Upper and lower gastrointestinal bleeding
Notes Funded by Health Technology Assessment programme, which is part of the National Institute for Health
Research (NIHR), UK
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D A T A A N D A N A L Y S E S
Comparison 1. Tranexamic acid vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 8 1701 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.42, 0.87]
2 Mortality scenario analysis,
treatment failure if participant
missing
8 1701 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.43, 1.81]
3 Mortality in trials with low risk
of bias
8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Allocation sequence
generation
1 516 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.26, 0.82]
3.2 Allocation concealment 7 1654 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.42, 0.89]
3.3 Blinding 7 1654 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.42, 0.89]
3.4 Incomplete outcome data 1 206 Risk Ratio (M-H, Random, 95% CI) 0.8 [0.22, 2.89]
3.5 Selective reporting 7 1651 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.41, 0.89]
4 Mortality in relation to
endoscopic therapy
8 1701 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.42, 0.87]
4.1 Endoscopic therapy not
used
6 1448 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.40, 0.88]
4.2 Endoscopic therapy used
to control bleeding
2 253 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.22, 2.00]
5 Mortality in relation to language
of publication
8 1701 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.42, 0.87]
5.1 Trials published in English 7 1654 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.42, 0.89]
5.2 Trials translated from
Russian
1 47 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.04, 3.38]
6 Rebleeding 7 1651 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.50, 1.03]
7 Rebleeding scenario analysis,
treatment failure if participant
missing
7 1651 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.51, 1.27]
8 Rebleeding in trials with low risk
of bias
7 5581 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.65, 0.93]
8.1 Allocation sequence
generation
1 516 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.83, 1.61]
8.2 Allocation concealment 6 1604 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.50, 1.07]
8.3 Blinding 6 1604 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.50, 1.07]
8.4 Incomplete outcome data 1 206 Risk Ratio (M-H, Random, 95% CI) 0.9 [0.38, 2.12]
8.5 Selective reporting 7 1651 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.50, 1.03]
9 Rebleeding in relation to
endoscopic therapy
7 1651 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.50, 1.03]
9.1 Endoscopic therapy not
used
5 1398 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.45, 1.08]
9.2 Endoscopic therapy used
to control bleeding
2 253 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.36, 1.62]
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10 Rebleeding in relation to
language of publication
7 1651 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.50, 1.03]
10.1 Trials published in
English
6 1604 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.50, 1.07]
10.2 Trials translated from
Russian
1 47 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.10, 2.11]
11 Myocardial infarction,
pulmonary embolism and
cerebral infarction
3 1048 Risk Ratio (M-H, Random, 95% CI) 1.37 [0.36, 5.28]
12 Deep venous thrombosis 3 1048 Risk Ratio (M-H, Random, 95% CI) 2.32 [0.60, 8.89]
13 Any thromboembolic event 4 1095 Risk Ratio (M-H, Random, 95% CI) 1.86 [0.66, 5.24]
14 Surgery 7 1551 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.35, 1.04]
15 Transfusion required 5 931 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.94, 1.11]
Comparison 2. Tranexamic acid vs cimetidine or lansoprazole
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 2 720 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.50, 1.64]
2 Bleeding 2 720 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.64, 1.20]
3 Surgery 2 720 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.54, 1.26]
4 Transfusion 2 720 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.78, 1.22]
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Analysis 1.1. Comparison 1 Tranexamic acid vs placebo, Outcome 1 Mortality.
Review: Tranexamic acid for upper gastrointestinal bleeding
Comparison: 1 Tranexamic acid vs placebo
Outcome: 1 Mortality
Study or subgroup Tranexamic acid Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bagnenko 2011 1/22 3/25 2.9 % 0.38 [ 0.04, 3.38 ]
Barer 1983 16/256 35/260 42.7 % 0.46 [ 0.26, 0.82 ]
Bergqvist 1980 3/25 5/25 7.9 % 0.60 [ 0.16, 2.25 ]
Biggs 1976 2/103 4/97 4.9 % 0.47 [ 0.09, 2.51 ]
Cormack 1973 3/76 3/74 5.6 % 0.97 [ 0.20, 4.67 ]
Engquist 1979 11/102 12/102 23.0 % 0.92 [ 0.42, 1.98 ]
Hawkey 2001 4/103 5/103 8.3 % 0.80 [ 0.22, 2.89 ]
Holstein 1987 2/164 4/164 4.8 % 0.50 [ 0.09, 2.69 ]
Total (95% CI) 851 850 100.0 % 0.60 [ 0.42, 0.87 ]
Total events: 42 (Tranexamic acid), 71 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.81, df = 7 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.68 (P = 0.0073)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Tranexamic acid vs placebo, Outcome 2 Mortality scenario analysis, treatment
failure if participant missing.
Review: Tranexamic acid for upper gastrointestinal bleeding
Comparison: 1 Tranexamic acid vs placebo
Outcome: 2 Mortality scenario analysis, treatment failure if participant missing
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bagnenko 2011 1/22 3/25 7.0 % 0.38 [ 0.04, 3.38 ]
Barer 1983 16/256 35/260 18.2 % 0.46 [ 0.26, 0.82 ]
Bergqvist 1980 7/25 5/25 14.6 % 1.40 [ 0.51, 3.82 ]
Biggs 1976 2/103 4/97 9.7 % 0.47 [ 0.09, 2.51 ]
Cormack 1973 3/76 3/74 10.4 % 0.97 [ 0.20, 4.67 ]
Engquist 1979 37/102 12/102 18.0 % 3.08 [ 1.71, 5.56 ]
Hawkey 2001 4/103 5/103 12.4 % 0.80 [ 0.22, 2.89 ]
Holstein 1987 2/164 4/164 9.6 % 0.50 [ 0.09, 2.69 ]
Total (95% CI) 851 850 100.0 % 0.88 [ 0.43, 1.81 ]
Total events: 72 (Tranexamic acid), 71 (Placebo)
Heterogeneity: Tau2 = 0.65; Chi2 = 23.73, df = 7 (P = 0.001); I2 =71%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Tranexamic acid vs placebo, Outcome 3 Mortality in trials with low risk of bias.
Review: Tranexamic acid for upper gastrointestinal bleeding
Comparison: 1 Tranexamic acid vs placebo
Outcome: 3 Mortality in trials with low risk of bias
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Allocation sequence generation
Barer 1983 16/256 35/260 100.0 % 0.46 [ 0.26, 0.82 ]
Subtotal (95% CI) 256 260 100.0 % 0.46 [ 0.26, 0.82 ]
Total events: 16 (Tranexamic acid), 35 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0079)
2 Allocation concealment
Barer 1983 16/256 35/260 44.0 % 0.46 [ 0.26, 0.82 ]
Bergqvist 1980 3/25 5/25 8.1 % 0.60 [ 0.16, 2.25 ]
Biggs 1976 2/103 4/97 5.0 % 0.47 [ 0.09, 2.51 ]
Cormack 1973 3/76 3/74 5.7 % 0.97 [ 0.20, 4.67 ]
Engquist 1979 11/102 12/102 23.7 % 0.92 [ 0.42, 1.98 ]
Hawkey 2001 4/103 5/103 8.5 % 0.80 [ 0.22, 2.89 ]
Holstein 1987 2/164 4/164 5.0 % 0.50 [ 0.09, 2.69 ]
Subtotal (95% CI) 829 825 100.0 % 0.61 [ 0.42, 0.89 ]
Total events: 41 (Tranexamic acid), 68 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.63, df = 6 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.57 (P = 0.010)
3 Blinding
Barer 1983 16/256 35/260 44.0 % 0.46 [ 0.26, 0.82 ]
Bergqvist 1980 3/25 5/25 8.1 % 0.60 [ 0.16, 2.25 ]
Biggs 1976 2/103 4/97 5.0 % 0.47 [ 0.09, 2.51 ]
Cormack 1973 3/76 3/74 5.7 % 0.97 [ 0.20, 4.67 ]
Engquist 1979 11/102 12/102 23.7 % 0.92 [ 0.42, 1.98 ]
Hawkey 2001 4/103 5/103 8.5 % 0.80 [ 0.22, 2.89 ]
Holstein 1987 2/164 4/164 5.0 % 0.50 [ 0.09, 2.69 ]
Subtotal (95% CI) 829 825 100.0 % 0.61 [ 0.42, 0.89 ]
Total events: 41 (Tranexamic acid), 68 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.63, df = 6 (P = 0.85); I2 =0.0%
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(. . . Continued)
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 2.57 (P = 0.010)
4 Incomplete outcome data
Hawkey 2001 4/103 5/103 100.0 % 0.80 [ 0.22, 2.89 ]
Subtotal (95% CI) 103 103 100.0 % 0.80 [ 0.22, 2.89 ]
Total events: 4 (Tranexamic acid), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
5 Selective reporting
Bagnenko 2011 1/22 3/25 3.1 % 0.38 [ 0.04, 3.38 ]
Barer 1983 16/256 35/260 46.4 % 0.46 [ 0.26, 0.82 ]
Biggs 1976 2/103 4/97 5.3 % 0.47 [ 0.09, 2.51 ]
Cormack 1973 3/76 3/74 6.0 % 0.97 [ 0.20, 4.67 ]
Engquist 1979 11/102 12/102 25.0 % 0.92 [ 0.42, 1.98 ]
Hawkey 2001 4/103 5/103 9.0 % 0.80 [ 0.22, 2.89 ]
Holstein 1987 2/164 4/164 5.2 % 0.50 [ 0.09, 2.69 ]
Subtotal (95% CI) 826 825 100.0 % 0.60 [ 0.41, 0.89 ]
Total events: 39 (Tranexamic acid), 66 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.81, df = 6 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 2.57 (P = 0.010)
Test for subgroup differences: Chi2 = 0.98, df = 4 (P = 0.91), I2 =0.0%
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Analysis 1.4. Comparison 1 Tranexamic acid vs placebo, Outcome 4 Mortality in relation to endoscopic
therapy.
Review: Tranexamic acid for upper gastrointestinal bleeding
Comparison: 1 Tranexamic acid vs placebo
Outcome: 4 Mortality in relation to endoscopic therapy
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Endoscopic therapy not used
Barer 1983 16/256 35/260 42.7 % 0.46 [ 0.26, 0.82 ]
Bergqvist 1980 3/25 5/25 7.9 % 0.60 [ 0.16, 2.25 ]
Biggs 1976 2/103 4/97 4.9 % 0.47 [ 0.09, 2.51 ]
Cormack 1973 3/76 3/74 5.6 % 0.97 [ 0.20, 4.67 ]
Engquist 1979 11/102 12/102 23.0 % 0.92 [ 0.42, 1.98 ]
Holstein 1987 2/164 4/164 4.8 % 0.50 [ 0.09, 2.69 ]
Subtotal (95% CI) 726 722 88.9 % 0.60 [ 0.40, 0.88 ]
Total events: 37 (Tranexamic acid), 63 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.45, df = 5 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 2.58 (P = 0.0098)
2 Endoscopic therapy used to control bleeding
Bagnenko 2011 1/22 3/25 2.9 % 0.38 [ 0.04, 3.38 ]
Hawkey 2001 4/103 5/103 8.3 % 0.80 [ 0.22, 2.89 ]
Subtotal (95% CI) 125 128 11.1 % 0.66 [ 0.22, 2.00 ]
Total events: 5 (Tranexamic acid), 8 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.46)
Total (95% CI) 851 850 100.0 % 0.60 [ 0.42, 0.87 ]
Total events: 42 (Tranexamic acid), 71 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.81, df = 7 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.68 (P = 0.0073)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.86), I2 =0.0%
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Analysis 1.5. Comparison 1 Tranexamic acid vs placebo, Outcome 5 Mortality in relation to language of
publication.
Review: Tranexamic acid for upper gastrointestinal bleeding
Comparison: 1 Tranexamic acid vs placebo
Outcome: 5 Mortality in relation to language of publication
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Trials published in English
Barer 1983 16/256 35/260 42.7 % 0.46 [ 0.26, 0.82 ]
Bergqvist 1980 3/25 5/25 7.9 % 0.60 [ 0.16, 2.25 ]
Biggs 1976 2/103 4/97 4.9 % 0.47 [ 0.09, 2.51 ]
Cormack 1973 3/76 3/74 5.6 % 0.97 [ 0.20, 4.67 ]
Engquist 1979 11/102 12/102 23.0 % 0.92 [ 0.42, 1.98 ]
Hawkey 2001 4/103 5/103 8.3 % 0.80 [ 0.22, 2.89 ]
Holstein 1987 2/164 4/164 4.8 % 0.50 [ 0.09, 2.69 ]
Subtotal (95% CI) 829 825 97.1 % 0.61 [ 0.42, 0.89 ]
Total events: 41 (Tranexamic acid), 68 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.63, df = 6 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.57 (P = 0.010)
2 Trials translated from Russian
Bagnenko 2011 1/22 3/25 2.9 % 0.38 [ 0.04, 3.38 ]
Subtotal (95% CI) 22 25 2.9 % 0.38 [ 0.04, 3.38 ]
Total events: 1 (Tranexamic acid), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
Total (95% CI) 851 850 100.0 % 0.60 [ 0.42, 0.87 ]
Total events: 42 (Tranexamic acid), 71 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.81, df = 7 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.68 (P = 0.0073)
Test for subgroup differences: Chi2 = 0.18, df = 1 (P = 0.67), I2 =0.0%
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Analysis 1.6. Comparison 1 Tranexamic acid vs placebo, Outcome 6 Rebleeding.
Review: Tranexamic acid for upper gastrointestinal bleeding
Comparison: 1 Tranexamic acid vs placebo
Outcome: 6 Rebleeding
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bagnenko 2011 2/22 5/25 4.7 % 0.45 [ 0.10, 2.11 ]
Barer 1983 58/256 51/260 25.5 % 1.16 [ 0.83, 1.61 ]
Biggs 1976 7/103 21/97 12.3 % 0.31 [ 0.14, 0.71 ]
Cormack 1973 8/76 11/74 11.5 % 0.71 [ 0.30, 1.66 ]
Engquist 1979 23/102 29/102 20.9 % 0.79 [ 0.49, 1.27 ]
Hawkey 2001 9/103 10/103 11.4 % 0.90 [ 0.38, 2.12 ]
Holstein 1987 10/164 19/164 13.8 % 0.53 [ 0.25, 1.10 ]
Total (95% CI) 826 825 100.0 % 0.72 [ 0.50, 1.03 ]
Total events: 117 (Tranexamic acid), 146 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 11.67, df = 6 (P = 0.07); I2 =49%
Test for overall effect: Z = 1.81 (P = 0.070)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Tranexamic acid vs placebo, Outcome 7 Rebleeding scenario analysis,
treatment failure if participant missing.
Review: Tranexamic acid for upper gastrointestinal bleeding
Comparison: 1 Tranexamic acid vs placebo
Outcome: 7 Rebleeding scenario analysis, treatment failure if participant missing
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bagnenko 2011 2/22 5/25 6.4 % 0.45 [ 0.10, 2.11 ]
Barer 1983 58/256 51/260 20.4 % 1.16 [ 0.83, 1.61 ]
Biggs 1976 7/103 21/97 13.4 % 0.31 [ 0.14, 0.71 ]
Cormack 1973 8/76 11/74 12.8 % 0.71 [ 0.30, 1.66 ]
Engquist 1979 49/102 29/102 19.9 % 1.69 [ 1.17, 2.44 ]
Hawkey 2001 9/103 10/103 12.7 % 0.90 [ 0.38, 2.12 ]
Holstein 1987 10/164 19/164 14.4 % 0.53 [ 0.25, 1.10 ]
Total (95% CI) 826 825 100.0 % 0.80 [ 0.51, 1.27 ]
Total events: 143 (Tranexamic acid), 146 (Placebo)
Heterogeneity: Tau2 = 0.24; Chi2 = 21.24, df = 6 (P = 0.002); I2 =72%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Tranexamic acid vs placebo, Outcome 8 Rebleeding in trials with low risk of bias.
Review: Tranexamic acid for upper gastrointestinal bleeding
Comparison: 1 Tranexamic acid vs placebo
Outcome: 8 Rebleeding in trials with low risk of bias
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Allocation sequence generation
Barer 1983 58/256 51/260 8.5 % 1.16 [ 0.83, 1.61 ]
Subtotal (95% CI) 256 260 8.5 % 1.16 [ 0.83, 1.61 ]
Total events: 58 (Tranexamic acid), 51 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
2 Allocation concealment
Hawkey 2001 9/103 10/103 3.2 % 0.90 [ 0.38, 2.12 ]
Barer 1983 58/256 51/260 8.5 % 1.16 [ 0.83, 1.61 ]
Biggs 1976 7/103 21/97 3.5 % 0.31 [ 0.14, 0.71 ]
Cormack 1973 8/76 11/74 3.2 % 0.71 [ 0.30, 1.66 ]
Holstein 1987 10/164 19/164 4.0 % 0.53 [ 0.25, 1.10 ]
Engquist 1979 23/102 29/102 6.6 % 0.79 [ 0.49, 1.27 ]
Subtotal (95% CI) 804 800 29.0 % 0.73 [ 0.50, 1.07 ]
Total events: 115 (Tranexamic acid), 141 (Placebo)
Heterogeneity: Tau2 = 0.11; Chi2 = 11.05, df = 5 (P = 0.05); I2 =55%
Test for overall effect: Z = 1.63 (P = 0.10)
3 Blinding
Hawkey 2001 9/103 10/103 3.2 % 0.90 [ 0.38, 2.12 ]
Biggs 1976 7/103 21/97 3.5 % 0.31 [ 0.14, 0.71 ]
Barer 1983 58/256 51/260 8.5 % 1.16 [ 0.83, 1.61 ]
Cormack 1973 8/76 11/74 3.2 % 0.71 [ 0.30, 1.66 ]
Holstein 1987 10/164 19/164 4.0 % 0.53 [ 0.25, 1.10 ]
Engquist 1979 23/102 29/102 6.6 % 0.79 [ 0.49, 1.27 ]
Subtotal (95% CI) 804 800 29.0 % 0.73 [ 0.50, 1.07 ]
Total events: 115 (Tranexamic acid), 141 (Placebo)
Heterogeneity: Tau2 = 0.11; Chi2 = 11.05, df = 5 (P = 0.05); I2 =55%
Test for overall effect: Z = 1.63 (P = 0.10)
4 Incomplete outcome data
Hawkey 2001 9/103 10/103 3.2 % 0.90 [ 0.38, 2.12 ]
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(. . . Continued)
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 103 103 3.2 % 0.90 [ 0.38, 2.12 ]
Total events: 9 (Tranexamic acid), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
5 Selective reporting
Bagnenko 2011 2/22 5/25 1.2 % 0.45 [ 0.10, 2.11 ]
Hawkey 2001 9/103 10/103 3.2 % 0.90 [ 0.38, 2.12 ]
Barer 1983 58/256 51/260 8.5 % 1.16 [ 0.83, 1.61 ]
Biggs 1976 7/103 21/97 3.5 % 0.31 [ 0.14, 0.71 ]
Cormack 1973 8/76 11/74 3.2 % 0.71 [ 0.30, 1.66 ]
Holstein 1987 10/164 19/164 4.0 % 0.53 [ 0.25, 1.10 ]
Engquist 1979 23/102 29/102 6.6 % 0.79 [ 0.49, 1.27 ]
Subtotal (95% CI) 826 825 30.2 % 0.72 [ 0.50, 1.03 ]
Total events: 117 (Tranexamic acid), 146 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 11.67, df = 6 (P = 0.07); I2 =49%
Test for overall effect: Z = 1.81 (P = 0.070)
Total (95% CI) 2793 2788 100.0 % 0.78 [ 0.65, 0.93 ]
Total events: 414 (Tranexamic acid), 489 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 36.82, df = 20 (P = 0.01); I2 =46%
Test for overall effect: Z = 2.75 (P = 0.0060)
Test for subgroup differences: Chi2 = 5.28, df = 4 (P = 0.26), I2 =24%
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Analysis 1.9. Comparison 1 Tranexamic acid vs placebo, Outcome 9 Rebleeding in relation to endoscopic
therapy.
Review: Tranexamic acid for upper gastrointestinal bleeding
Comparison: 1 Tranexamic acid vs placebo
Outcome: 9 Rebleeding in relation to endoscopic therapy
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Endoscopic therapy not used
Barer 1983 58/256 51/260 25.5 % 1.16 [ 0.83, 1.61 ]
Biggs 1976 7/103 21/97 12.3 % 0.31 [ 0.14, 0.71 ]
Cormack 1973 8/76 11/74 11.5 % 0.71 [ 0.30, 1.66 ]
Engquist 1979 23/102 29/102 20.9 % 0.79 [ 0.49, 1.27 ]
Holstein 1987 10/164 19/164 13.8 % 0.53 [ 0.25, 1.10 ]
Subtotal (95% CI) 701 697 83.9 % 0.70 [ 0.45, 1.08 ]
Total events: 106 (Tranexamic acid), 131 (Placebo)
Heterogeneity: Tau2 = 0.15; Chi2 = 11.04, df = 4 (P = 0.03); I2 =64%
Test for overall effect: Z = 1.60 (P = 0.11)
2 Endoscopic therapy used to control bleeding
Bagnenko 2011 2/22 5/25 4.7 % 0.45 [ 0.10, 2.11 ]
Hawkey 2001 9/103 10/103 11.4 % 0.90 [ 0.38, 2.12 ]
Subtotal (95% CI) 125 128 16.1 % 0.77 [ 0.36, 1.62 ]
Total events: 11 (Tranexamic acid), 15 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 826 825 100.0 % 0.72 [ 0.50, 1.03 ]
Total events: 117 (Tranexamic acid), 146 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 11.67, df = 6 (P = 0.07); I2 =49%
Test for overall effect: Z = 1.81 (P = 0.070)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
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Analysis 1.10. Comparison 1 Tranexamic acid vs placebo, Outcome 10 Rebleeding in relation to language of
publication.
Review: Tranexamic acid for upper gastrointestinal bleeding
Comparison: 1 Tranexamic acid vs placebo
Outcome: 10 Rebleeding in relation to language of publication
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Trials published in English
Barer 1983 58/256 51/260 25.5 % 1.16 [ 0.83, 1.61 ]
Biggs 1976 7/103 21/97 12.3 % 0.31 [ 0.14, 0.71 ]
Cormack 1973 8/76 11/74 11.5 % 0.71 [ 0.30, 1.66 ]
Engquist 1979 23/102 29/102 20.9 % 0.79 [ 0.49, 1.27 ]
Hawkey 2001 9/103 10/103 11.4 % 0.90 [ 0.38, 2.12 ]
Holstein 1987 10/164 19/164 13.8 % 0.53 [ 0.25, 1.10 ]
Subtotal (95% CI) 804 800 95.3 % 0.73 [ 0.50, 1.07 ]
Total events: 115 (Tranexamic acid), 141 (Placebo)
Heterogeneity: Tau2 = 0.11; Chi2 = 11.05, df = 5 (P = 0.05); I2 =55%
Test for overall effect: Z = 1.63 (P = 0.10)
2 Trials translated from Russian
Bagnenko 2011 2/22 5/25 4.7 % 0.45 [ 0.10, 2.11 ]
Subtotal (95% CI) 22 25 4.7 % 0.45 [ 0.10, 2.11 ]
Total events: 2 (Tranexamic acid), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Total (95% CI) 826 825 100.0 % 0.72 [ 0.50, 1.03 ]
Total events: 117 (Tranexamic acid), 146 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 11.67, df = 6 (P = 0.07); I2 =49%
Test for overall effect: Z = 1.81 (P = 0.070)
Test for subgroup differences: Chi2 = 0.35, df = 1 (P = 0.56), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours tranexamic acid Favours placebo
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Analysis 1.11. Comparison 1 Tranexamic acid vs placebo, Outcome 11 Myocardial infarction, pulmonary
embolism and cerebral infarction.
Review: Tranexamic acid for upper gastrointestinal bleeding
Comparison: 1 Tranexamic acid vs placebo
Outcome: 11 Myocardial infarction, pulmonary embolism and cerebral infarction
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Barer 1983 1/256 0/260 17.6 % 3.05 [ 0.12, 74.44 ]
Engquist 1979 4/102 2/102 62.8 % 2.00 [ 0.37, 10.68 ]
Holstein 1987 0/164 2/164 19.6 % 0.20 [ 0.01, 4.13 ]
Total (95% CI) 522 526 100.0 % 1.37 [ 0.36, 5.28 ]
Total events: 5 (Tranexamic acid), 4 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.03, df = 2 (P = 0.36); I2 =1%
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Tranexamic acid vs placebo, Outcome 12 Deep venous thrombosis.
Review: Tranexamic acid for upper gastrointestinal bleeding
Comparison: 1 Tranexamic acid vs placebo
Outcome: 12 Deep venous thrombosis
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Barer 1983 1/256 0/260 17.7 % 3.05 [ 0.12, 74.44 ]
Engquist 1979 4/102 2/102 64.5 % 2.00 [ 0.37, 10.68 ]
Holstein 1987 1/164 0/164 17.8 % 3.00 [ 0.12, 73.11 ]
Total (95% CI) 522 526 100.0 % 2.32 [ 0.60, 8.89 ]
Total events: 6 (Tranexamic acid), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Tranexamic acid vs placebo, Outcome 13 Any thromboembolic event.
Review: Tranexamic acid for upper gastrointestinal bleeding
Comparison: 1 Tranexamic acid vs placebo
Outcome: 13 Any thromboembolic event
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bagnenko 2011 0/22 0/25 Not estimable
Barer 1983 5/256 2/260 40.3 % 2.54 [ 0.50, 12.97 ]
Engquist 1979 5/102 2/102 41.0 % 2.50 [ 0.50, 12.59 ]
Holstein 1987 1/164 2/164 18.7 % 0.50 [ 0.05, 5.46 ]
Total (95% CI) 544 551 100.0 % 1.86 [ 0.66, 5.24 ]
Total events: 11 (Tranexamic acid), 6 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.43, df = 2 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Tranexamic acid vs placebo, Outcome 14 Surgery.
Review: Tranexamic acid for upper gastrointestinal bleeding
Comparison: 1 Tranexamic acid vs placebo
Outcome: 14 Surgery
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bagnenko 2011 1/22 3/25 5.0 % 0.38 [ 0.04, 3.38 ]
Barer 1983 47/256 40/260 22.8 % 1.19 [ 0.81, 1.75 ]
Bergqvist 1980 7/25 7/25 15.2 % 1.00 [ 0.41, 2.43 ]
Biggs 1976 7/103 21/97 16.4 % 0.31 [ 0.14, 0.71 ]
Engquist 1979 10/102 18/102 17.7 % 0.56 [ 0.27, 1.14 ]
Hawkey 2001 5/103 6/103 11.9 % 0.83 [ 0.26, 2.64 ]
Holstein 1987 3/164 15/164 11.2 % 0.20 [ 0.06, 0.68 ]
Total (95% CI) 775 776 100.0 % 0.61 [ 0.35, 1.04 ]
Total events: 80 (Tranexamic acid), 110 (Placebo)
Heterogeneity: Tau2 = 0.30; Chi2 = 16.21, df = 6 (P = 0.01); I2 =63%
Test for overall effect: Z = 1.82 (P = 0.069)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Tranexamic acid vs placebo, Outcome 15 Transfusion required.
Review: Tranexamic acid for upper gastrointestinal bleeding
Comparison: 1 Tranexamic acid vs placebo
Outcome: 15 Transfusion required
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bagnenko 2011 14/22 13/25 3.1 % 1.22 [ 0.75, 2.00 ]
Biggs 1976 77/103 71/97 27.3 % 1.02 [ 0.87, 1.20 ]
Cormack 1973 68/76 63/74 49.3 % 1.05 [ 0.93, 1.19 ]
Hawkey 2001 58/103 60/103 13.3 % 0.97 [ 0.76, 1.22 ]
Holstein 1987 47/164 54/164 7.0 % 0.87 [ 0.63, 1.21 ]
Total (95% CI) 468 463 100.0 % 1.02 [ 0.94, 1.11 ]
Total events: 264 (Tranexamic acid), 261 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.27, df = 4 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Tranexamic acid vs cimetidine or lansoprazole, Outcome 1 Mortality.
Review: Tranexamic acid for upper gastrointestinal bleeding
Comparison: 2 Tranexamic acid vs cimetidine or lansoprazole
Outcome: 1 Mortality
Study or subgroup Tranexamic acid
Cimetidine or
lansoprazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Barer 1983 16/256 20/259 87.5 % 0.81 [ 0.43, 1.53 ]
Hawkey 2001 4/103 2/102 12.5 % 1.98 [ 0.37, 10.58 ]
Total (95% CI) 359 361 100.0 % 0.91 [ 0.50, 1.64 ]
Total events: 20 (Tranexamic acid), 22 (Cimetidine or lansoprazole)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
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Favours experimental Favours control
Analysis 2.2. Comparison 2 Tranexamic acid vs cimetidine or lansoprazole, Outcome 2 Bleeding.
Review: Tranexamic acid for upper gastrointestinal bleeding
Comparison: 2 Tranexamic acid vs cimetidine or lansoprazole
Outcome: 2 Bleeding
Study or subgroup Tranexamic acid
Cimetidine or
lansoprazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Barer 1983 50/256 58/259 86.7 % 0.87 [ 0.62, 1.22 ]
Hawkey 2001 9/103 10/102 13.3 % 0.89 [ 0.38, 2.10 ]
Total (95% CI) 359 361 100.0 % 0.87 [ 0.64, 1.20 ]
Total events: 59 (Tranexamic acid), 68 (Cimetidine or lansoprazole)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Tranexamic acid vs cimetidine or lansoprazole, Outcome 3 Surgery.
Review: Tranexamic acid for upper gastrointestinal bleeding
Comparison: 2 Tranexamic acid vs cimetidine or lansoprazole
Outcome: 3 Surgery
Study or subgroup Tranexamic acid
Cimetidine or
lansoprazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Barer 1983 36/256 47/259 91.2 % 0.77 [ 0.52, 1.15 ]
Hawkey 2001 5/103 3/102 8.8 % 1.65 [ 0.41, 6.73 ]
Total (95% CI) 359 361 100.0 % 0.83 [ 0.54, 1.26 ]
Total events: 41 (Tranexamic acid), 50 (Cimetidine or lansoprazole)
Heterogeneity: Tau2 = 0.01; Chi2 = 1.03, df = 1 (P = 0.31); I2 =3%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Tranexamic acid vs cimetidine or lansoprazole, Outcome 4 Transfusion.
Review: Tranexamic acid for upper gastrointestinal bleeding
Comparison: 2 Tranexamic acid vs cimetidine or lansoprazole
Outcome: 4 Transfusion
Study or subgroup Tranexamic acid
Cimetidine or
lansoprazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Barer 1983 149/256 140/259 56.3 % 1.08 [ 0.92, 1.25 ]
Hawkey 2001 58/103 67/102 43.7 % 0.86 [ 0.69, 1.07 ]
Total (95% CI) 359 361 100.0 % 0.97 [ 0.78, 1.22 ]
Total events: 207 (Tranexamic acid), 207 (Cimetidine or lansoprazole)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.78, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours experimental Favours control
A D D I T I O N A L T A B L E S
Table 1. Adverse events
Trial Serious adverse events Non-serious
adverse events
Non-serious
adverse events
Tranexamic acid Control group Intervention group
not specified
Tranexamic acid Control group
Barer 1983 Fatal stroke (n = 1) Confusion
(n = 1)
Pul-
monary embolism (n
= 5). Myocardial in-
farction (n = 8)
None described Confusion (n = 1)
Biggs 1976 None described None described None described Thrombophlebitis at
injection site (n = 3)
. Nausea or headache
(n = 4)
Thrombophlebitis at
injection site (n = 2)
. Nausea or headache
(n = 5). Fever (n = 2)
Engquist 1979 Pul-
monary embolism (n
= 2). Myocardial in-
farction (n = 2)
Cerebral infarction
(n = 2)
None described None described None described
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Table 1. Adverse events (Continued)
Hawkey 2001 None described None described Several participants
expe-
rienced thromboem-
bolic complications.
The numbers were
described as not sig-
nificantly different in
treatment and con-
trol groups, but no
specific data are pro-
vided
None described None described
Holstein 1987 None described Cerebral infarction
(n = 2)
Five additional par-
ticipants were ex-
cluded as the result
of thromboembolic
disease, but whether
these partici-
pants were randomly
assigned to tranex-
amic acid or placebo
is not reported
Nausea and vomit-
ing, tachycardia (n
= 3). Hypotension
(n = 3). Throm-
bophlebitis at injec-
tion site (n = 2).
Deep venous throm-
bosis (n = 1)
None described
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
CENTRAL July 2014
#1 stomach or antrum or antral or pyloric or pylorus or gastri* or epigastr* or duodenal or duodenum or gastro-duodenal or gastro-
duodenal or oeso*ag* or esp*ag* or upper GI or UGI or upper gastrointestinal
#2 h*emorrhag* or bleed* or re-bleed* or rebleed*
#3 (#1 AND #2)
#4 MeSH descriptor Gastrointestinal Hemorrhage explode all trees
#5 Gastrointestinal Hemorrhage
#6 h*ematemesis
#7 (#3 OR #4 OR #5)
#8 tranexamic acid or amchafibrin or anvitoff or cyklokapron or Espercil or exacyl or lysteda or spotof or t-amcha or tranhexamic acid
or transamin or Transcam or ugurol
#9 (#7 AND #6)
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Appendix 2. MEDLINE search strategy
Ovid MEDLINE 1950 to July 2014
1. (stomach or antrum or antral or pyloric or pylorus or gastri$ or epigastr$ or duodenal or duodenum or gastro-duodenal or
gastroduodenal or oeso*ag* or esp*ag* or “upper GI” or UGI or “upper gastrointestinal ”).mp. [mp=title, original title, abstract, name
of substance word, subject heading word, unique identifier]
2. (h*emorrhag$ or bleed$ or re-bleed$ or rebleed$).mp. [mp=title, original title, abstract, name of substance word, subject heading
word, unique identifier]
3. 1 and 2
4. exp Gastrointestinal Hemorrhage/
5. h*ematemesis.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
6. or/3-5
7. (“tranexamic acid” or amchafibrin or anvitoff or cyklokapron or Espercil or exacyl or lysteda or spotof or t-amcha or “tranhexamic
acid” or transamin or Transcam or ugurol).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique
identifier]
8. 6 and 7
9. randomized controlled trial.pt.
10. controlled clinical trial.pt.
11. randomized.ab.
12. placebo.ab.
13. drug therapy.fs.
14. randomly.ab.
15. trial.ab.
16. groups.ab.
17. or/9-16
18. exp animals/ not humans.sh.
19. 17 not 18
20. 8 and 19
Appendix 3. EMBASE search strategy
EMBASE 1980 to July 2014
1. (stomach or antrum or antral or pyloric or pylorus or gastri$ or epigastr$ or duodenal or duodenum or gastro-duodenal or
gastroduodenal or oeso*ag* or esp*ag* or “upper GI” or UGI).mp. [mp=title, abstract, subject headings, heading word, drug trade
name, original title, device manufacturer, drug manufacturer name]
2. (h*emorrhag$ or bleed$ or re-bleed$ or rebleed$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer name]
3. 1 and 2
4. gastrointestinal hemorrhage/
5. duodenum bleeding/ or stomach hemorrhage/ or upper gastrointestinal bleeding/
6. h*ematemesis.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
7. or/3-6
8. (“tranexamic acid” or amchafibrin or anvitoff or cyklokapron or Espercil or exacyl or lysteda or spotof or t-amcha or “tranhexamic
acid” or transamin or Transcam or ugurol).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer name]
9. 7 and 8
10. Clinical trial/
11. Randomized controlled trial/
12. Randomization/
13. Single-Blind Method/
14. Double-Blind Method/
15. Cross-Over Studies/
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16. Random Allocation/
17. Placebo/
18. Randomi?ed controlled trial$.tw.
19. Rct.tw.
20. Random allocation.tw.
21. Randomly allocated.tw.
22. Allocated randomly.tw.
23. (allocated adj2 random).tw.
24. Single blind$.tw.
25. Double blind$.tw.
26. ((treble or triple) adj blind$).tw.
27. Placebo$.tw.
28. Prospective study/
29. or/10-28
30. Case study/
31. Case report.tw.
32. Abstract report/ or letter/
33. or/30-32
34. 29 not 33
35. 9 and 34
Appendix 4. Science Citation Index search strategy
# 7 #6 AND #5
# 6 TS=(random* or blind* or placebo* or meta-analysis)
# 5 #4 AND #3
# 4 TS=(tranexamic acid)
# 3 #2 AND #1
# 2 TS=(oeso*ag* or eso*ag* or stomach or gastric or ventricular or duodenum)
# 1 TS=(bleeding or hemorrhage or haemorrhage or re-bleeding or (recurren* and (bleed* or haemorrhage or hemorrhage)))
Appendix 5. International Clinical Trials Registry Platform (ICTRP) search strategy
ICTRP July 2014
(bleedingOR “BLEEDING”OR “Blood Loss” OR “EXTRAVASATIONBLOOD”OR “HAEMORRHAGENOS”OR “HEM”OR
“hemorrhage” OR “HEMORRHAGE (NOS)” OR “HEMORRHAGE NOS” OR “Hemorrhage, unspecified” OR “Hemorrhages”
OR “Loss of blood” tranexamic acid OR “Acid, Tranexamic” OR “AMCA” OR “AMCHA” OR “Cyclokapron” OR “Cyklokapron”
OR “t-AMCHA” OR “TRANEXAMIC ACID” OR “trans-4-(Aminomethyl)cyclohexanecarboxylic Acid” AND (tranexamic acid OR
“Acid, Tranexamic” OR “AMCA” OR “AMCHA” OR “Cyclokapron” OR “Cyklokapron” OR “t-AMCHA” OR “TRANEXAMIC
ACID” OR). “trans-4-(Aminomethyl)cyclohexanecarboxylic Acid”)).
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Appendix 6. Search results
Eighty records were identified by initial electronic searches of the following databases.
• CENTRAL: 10 citations.
• MEDLINE: 22 citations.
• EMBASE: 62 citations.
• Science Citation Index: 6 citations.
Thirty-seven additional records were identified in the search update performed July 2014 (Figure 1).
WH A T ’ S N E W
Last assessed as up-to-date: 29 July 2014.
Date Event Description
29 July 2014 New search has been performed We originally planned to perform separate analyses on
continued bleeding and rebleeding, but we were unable
to extract the necessary data from the included trials
We have updated the assessment of bias according to the
recommendations provided in the Cochrane Handbook for
Systematic Reviews of Interventions of The Cochrane Col-
laboration
29 July 2014 New citation required but conclusions have not changed One additional randomised controlled trial has been in-
cluded in the analyses. The addition of this trial has not
changed our conclusions
C O N T R I B U T I O N S O F A U T H O R S
LLG drafted the review and performed the statistical analyses. SLK and ELA participated in interpretation of the results and revision
of the review. All review authors have approved the final version.
D E C L A R A T I O N S O F I N T E R E S T
None of the review authors has reported any conflicts of interest with regard to the present work.
CB is the proprietor of Systematic Research Ltd and was paid by the CUGPD Editorial Group for her contributions to this review.
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S O U R C E S O F S U P P O R T
Internal sources
• The present review did not receive funding, Other.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We updated the review in 2014 to comply with MECIR standards for the conduct and reporting of systematic reviews. We updated
the format of the review for clarity and provided the following information about our methods.
• We included adverse effects as a primary outcome (formerly a secondary outcome) to comply with recent guidance on conduct
and presentation of the systematic review.
• We clarified that because of the risk of selection bias in the allocation of participants to intervention or control groups and bias
in the administration of collateral interventions, we did not include cluster-randomised trials.
• For trials with multiple intervention groups, we partitioned the numbers of participants in individual allocation arms into pair-
wise comparisons.
• We used simple imputation to evaluate the potential influence of missing data: imputing failures, imputing successes, worst- and
best-case.
• We provided additional explanations of our assessment and reporting of heterogeneity for clarity; our methods remain
unchanged.
• We performed all meta-analyses using both random-effects and fixed-effect models. Fixed-effect meta-analyses are reported only
when results of the two models differ (e.g. one model shows no difference between interventions and the other shows an intervention
effect).
• We performed separate analyses of trials on tranexamic acid versus placebo or no intervention and trials on tranexamic acid
versus antiulcer drugs. We performed subgroup analyses of trials with low risk of bias based on assessment of the separate domains.
We also analysed subgroups of trials that used endoscopic therapy and trials published in English or Russian.
• We performed an analysis when all participants with missing outcome data were included as treatment failures, and we used a
per-protocol analysis to evaluate the influence of missing data when we excluded participants with missing outcome data.
• For analyses with at least 10 trials, we planned to assess reporting biases and other dissemination biases on the basis of funnel
plots (Higgins 2011) and regression analyses by using Harbord’s modified test (Harbord 2006). Our analyses included only eight
trials; therefore we did not carry out statistical analysis of reporting bias.
• We performed a post hoc trial sequential analysis to evaluate the risk of bias associated with cumulative testing and to evaluate
futility in assessment of mortality and bleeding (Higgins 2008; Wetterslev 2008). We performed the analysis with power set to 80%,
alpha to 5%, model-based diversity and relative risk reduction (RRR) to 25%. We set the control group incidence to 8% in our
analysis of mortality and to 18% in our analysis of bleeding.
• We prepared a ’Summary of findings’ table (Guyatt 2008) using GRADEpro software (Gradepro 3.6) and included information
on results of our primary outcomes in relation to risk of heterogeneity, duration of follow-up and quality of the evidence.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Oral; Aluminum Hydroxide [therapeutic use]; Anti-Ulcer Agents [therapeutic use]; Antifibrinolytic Agents [adverse
effects; ∗therapeutic use]; Cimetidine [therapeutic use]; Drug Combinations; Endoscopy, Gastrointestinal; Gastrointestinal Hemor-
rhage [∗drug therapy; mortality]; Injections, Intravenous; Lansoprazole [therapeutic use]; Magnesium [therapeutic use]; Magnesium
Hydroxide [therapeutic use]; Randomized Controlled Trials as Topic; Tranexamic Acid [adverse effects; ∗therapeutic use]
MeSH check words
Humans
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